CONTENTS

Issue 83 | June 2019

In association with

goodbye mr gottlieb

Looking back at Scott Gottlieb's two year tenure at the helm of the FDA

Pharmaoffer

A digital platform is helping drugmakers to connect with qualified material suppliers

The future of parkinson's

Could GDNF still form the basis for an effective Parkinson’s therapy?

CBD: myth vs medicine

Seperating the fact from fiction surrounding pharmaceutical CBD

pregnancy proteins

A pregnancy protein could form the foundation for new drugs

underground resistance

Sewage samples suggest that bad sanitation is driving antimicrobial resistance

Go to article: Home | Ingredients on demandGo to article: In this issueGo to article: Scandinavian HealthGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Hapa Company InsightGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The pharma industry briefingGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Scott Gottlieb: achievements of the outgoing FDA commissionerGo to article: CapsugelGo to article: AlpexGo to article: Can Pharmaoffer become the Amazon of pharma raw materials?Go to article: Molnar Company InsightGo to article: MolnarGo to article: Is growth factor protein the future of Parkinson’s treatment?Go to article: AEB Company Insight Go to article: AEB Go to article: CBD: the myth, the magic and the real deal drugsGo to article: Swiss WorldCargoGo to article: Moehs Iberica SLGo to article: Could a pregnancy protein hold promise for new drugs?Go to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Antimicrobial resistance: sewage samples reveal bad sanitation as a key driverGo to article: BEAGo to article: 3MGo to article: PfanstiehlGo to article: EventsGo to article: Richter HelmGo to article: Event: CPhl KoreaGo to article: TSS Company InsightGo to article: TSS ABGo to article: Next issueGo to article: Baxter